Focusing on bio-pharmaceuiticals
2001, Virchow Biotech Private Limited(VBPL), the bio-pharmaceutical
company of the group focuses on the manufacture of a wide
range of biologicals and bio-generics by genetic engineering
or classical fermentation. VBPL's achievements include being
the first to commercialise in India the bio-generic of the
only genetically engineered product for wound healing (PDGF)
to have been approved by the United States Food and Drug
Administration. Currently the product portfolio consists
of four products with five other recombinant bio-generics
in pi peline. VBPL's GMP certified facilities consist of
five independent production suites, which when fully complete
will have a total built-up area of 1,25,000 sq. ft. The
facilities are equi pped to manufacture products ranging
from oral biologicals, recombinants to parenteral bio-pharmaceuticals.
The equi pment include Fermentors (3 lt. to 1000 lt.), Preparative
HPLC systems, Ultrafiltration units, Lyophilizers, Pre-filled
syringe lines, etc. The facilities also include a fully
equi pped Animal Research Facility that routinely undertakes
Acute, Sub Chronic and Chronic preclinical toxicology trials.
VBPL also monitors and conducts large multi-centric clinical
trials and is a Govt. of India recognised R&D centre.
Injectable for treatment of osteoporosis
VIPEG (PEGYLATED INTERFERON)
Injectable for treatment of Hepatitis B & Hepatitis C
HEALACE GEL (rhPDGF-BB):
Topical product indicated for the treatment of
chronic non healing full thickness
neuropathic diabetic ulcers.
HYOPT (Sodium Hyaluronate B.P. - Ocular Grade):
Viscodispersive for the
use in Intra ocular surgeries.
HYORTH (Sodium Hyaluronate B.P. -
for the treatment of Osteoarthritis.